论文部分内容阅读
目的:探讨黄芪颗粒联合氯雷他啶治疗小儿咳嗽变异性哮喘的临床效果。方法:选取咳嗽变异性哮喘患儿60例,随机分为观察组与对照组各30例。对照组患儿给予黄芪颗粒治疗,观察组患儿给予黄芪颗粒联合氯雷他啶治疗。观察两组患儿治疗效果、咳嗽消失时间、呼吸道感染次数、哮喘发作次数。结果:经联合治疗后,观察组患儿总有效率明显高于对照组,两组比较差异有统计学意义(P<0.05);观察组患儿咳嗽时间、呼吸道感染次数、哮喘发作次数明显低于对照组,差异有统计学意义(P<0.05)。结论:黄芪颗粒联合氯雷他啶治疗小儿咳嗽变异性哮喘能有效缩短咳嗽消失时间,明显减少呼吸道感染次数、哮喘发作次数,临床效果确切,值得临床推广应用。
Objective: To investigate the clinical effect of astragalus granule combined with loratadine in treating children with cough variant asthma. Methods: Sixty children with cough variant asthma were randomly divided into observation group (30 cases) and control group (30 cases). Control group of children given Astragalus Granules treatment, the observation group given Astragalus granules combined loratadine treatment. The therapeutic effect of the two groups were observed, the time of cough disappeared, the number of respiratory infections and the number of asthma attacks. Results: After the combination therapy, the total effective rate in the observation group was significantly higher than that in the control group, with significant difference between the two groups (P <0.05). The cough time, the number of respiratory infections and the number of asthma attacks in the observation group were significantly lower In the control group, the difference was statistically significant (P <0.05). Conclusion: Astragalus membranaceus combined with loratadine in children with cough variant asthma can shorten the time of cough disappearance, significantly reduce the number of respiratory infections, the number of asthma attacks, the clinical effect is exact, worthy of clinical application.